The trajectory of Viagra presents a intricate picture for those considering investment. While the initial launch generated massive gains, the lapse of its intellectual property protection opened the floodgates to off-brand alternatives, dramatically diminishing market share. This creates a particular dilemma for pharmaceutical companies relying on

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in income, its exclusivity period created a flood of lower-priced alternatives , significantly diminishing its dominance. While specific businesses may try to capitalize on male sexual dysfunctio